Oct 22 (Reuters) - Medical equipment maker Thermo Fisher

beat analysts' estimates for third-quarter revenue and

profit on Wednesday, owing to strong demand for its tools and

technologies that are used to develop therapies.

Contract research firms such as Thermo Fisher are seeing

renewed demand as pharmaceutical companies ramp up drug

development and manufacturing, while benefiting from easing

trade tensions.

The Trump administration has extended some tariff exclusions

in China through November 29, but signaled potential new duties,

prompting Beijing to threaten countermeasures.

China is a key source of raw ingredients and supplies for

the pharmaceutical and medical device industries across the

world. It represents about 8% of Thermo Fisher's business.

The Waltham, Massachusetts-based company reported quarterly

revenue of $11.12 billion, compared with analysts' estimate of

$10.91 billion, according to data compiled by LSEG.

Sales at its laboratory products and biopharma services

segment, which makes up more than half of the company's total

sales, rose 4% to $5.97 billion.

Peer Danaher also beat quarterly estimates earlier this

week, buoyed by resilient demand for its diagnostic testing

tools and services.

Earlier this year, Thermo had said it would buy Sanofi's New

Jersey manufacturing site to produce critical medicines. It also

agreed to acquire Solventum's purification and filtration

business for about $4.1 billion to expand in bioprocessing.

The company posted an adjusted per-share profit of $5.79 for

the quarter ended September 27, while analysts estimated $5.49.

It will provide updated 2025 forecast during its earnings

conference call later in the day.

(Reporting by Sahil Pandey and Christy Santhosh in Bengaluru)